Opthea to Host Investor Days in New York and Australia
MWN-AI** Summary
Opthea Limited (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company focused on innovative therapies for retinal diseases, has announced a series of upcoming Investor Days in New York City and Australia. These events will feature updates on the company’s development plans for its lead candidate, sozinibercept, which targets wet age-related macular degeneration (wet AMD).
The New York City event is scheduled for January 28, 2025, at 1:30 PM ET, and will showcase presentations from notable retina expert, Dr. Charles C. Wykoff, along with Opthea’s senior management team led by Chief Commercial Officer, Mike Campbell. The presentations will cover critical discussions regarding the significant medical need for improved vision outcomes in wet AMD patients and the transformative potential of sozinibercept, particularly in combination with existing anti-VEGF-A therapies. This event will also feature a Q&A session to engage with investors and stakeholders.
Following New York, Opthea will conduct in-person sessions in Australia, specifically in Sydney on February 3 and Melbourne on February 5, at 4:30 PM AEDT. These gatherings aim to further articulate the company’s commercial strategies and readiness for sozinibercept as it approaches pivotal data readouts from two key trials, COAST and ShORe, scheduled for early and mid-2025, respectively.
Mike Campbell brings extensive experience in biotech and pharmaceutical marketing to Opthea, having played instrumental roles in the launch of other retinal therapies. Dr. Wykoff, a recognized figure in vitreoretinal research, serves as the Chief Investigator for Opthea's pivotal COAST trial.
As Opthea moves forward, these investor events will be crucial opportunities for stakeholders to gain insights into the company’s promising approach to treating wet AMD. Interested individuals can register or access the webcast through the Investor section of Opthea's website.
MWN-AI** Analysis
Opthea Limited (ASX/NASDAQ:OPT) is poised for significant engagement with investors through its upcoming Investor Days in New York, Sydney, and Melbourne. Scheduled for January 28, February 3, and February 5, respectively, these events present a pivotal moment for Opthea to communicate its strategic vision and highlight commercial insights into its lead product candidate, sozinibercept, targeting wet age-related macular degeneration (AMD).
Recent market sentiment around retinal disease treatments underscores an increasing demand for innovative therapies that improve patient outcomes. With the imminent topline data readouts from critical Phase 3 trials (COAST and ShORe), the narrative surrounding sozinibercept holds substantial potential. Management's presentations, particularly from seasoned professionals like Dr. Charles Wykoff and Chief Commercial Officer Mike Campbell, will likely offer deep insights into competitive positioning and the anticipated clinical efficacy of sozinibercept when used in conjunction with existing anti-VEGF-A therapies.
Investors should carefully evaluate the commercial readiness plans discussed during these events. Updates on market strategy, including pricing, physician engagement, and distribution channels, are essential for assessing the product's potential market entry and acceptance. Given Mr. Campbell's extensive background in launching retinal therapies, his insights are particularly valuable and may cement investor confidence.
As Opthea prepares to broaden its visibility and credibility through these Investor Days, interested stakeholders should monitor the discussion points carefully, particularly regarding anticipated outcomes from the COAST and ShORe trials. Engaging during Q&A sessions could further clarify market dynamics and competitive landscapes. Overall, Opthea represents a compelling opportunity for investors seeking exposure in the burgeoning field of ophthalmic therapeutics, especially in light of increasing enthusiasm around innovative treatment options for wet AMD.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Updates on commercial insights and readiness plans for sozinibercept in wet AMD
Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET
In-person events in Sydney on February 3 and Melbourne on February 5
MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February.
As the Company prepares for the anticipated topline data readout of its two pivotal trials, COAST in early CY Q2 2025 and ShORe in mid-CY 2025, the New York in-person event and live webcast will feature presentations from international retina thought leader Charles C. Wykoff, MD, PhD and Opthea’s senior management team, including Chief Commercial Officer Mike Campbell. Opthea’s Investor Day will highlight the following:
- The continued medical need for better vision outcomes in wet AMD and the opportunity for sozinibercept to transform patient lives with superior vision gains.
- New insights on the commercial potential and commercial readiness plans for sozinibercept in combination with standard-of-care anti-VEGF-A therapies.
It is expected that the presentations, followed by a question-and-answer session, will conclude by approximately 3:00 PM ET. Following the live webcast, a replay will be made available on the Company’s website.
The Company’s senior management will also host in-person investor presentations in Sydney on Monday February 3 at 4:30 PM AEDT and Melbourne on Wednesday February 5 at 4:30 PM AEDT.
Links to register or access the webcast will be available on the Investor Section of the Company’s website under “Events and Presentations” here .
About Charles C. Wykoff, MD, PhD
Charles C. Wykoff, MD, PhD is a board-certified retina specialist with Retina Consultants of Texas (RCTX). Leading a top international research facility for vitreoretinal diseases, Dr. Wykoff serves as Director of Research at RCTX and is Chair of Research and Clinical Trials at Retina Consultants of America. In addition, he serves as the elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital, and Clinical Professor of Ophthalmology, Weill Cornell Medical College. Dr. Wykoff has been awarded multiple Achievement, Honor and Senior Honor Awards and has published over 350 peer-reviewed manuscripts. Dr. Wykoff serves as the Chief Investigator for Opthea’s COAST Phase 3 pivotal trial and is Co-Chair of the COAST and ShORe Steering Committee.
About Mike Campbell, Chief Commercial Officer, Opthea
Mr. Campbell brings 30 years of biotech and pharmaceutical commercial leadership experience across sales, marketing, market access, patient services, and operations to the Company. He dedicated most of his career to launching and commercializing innovative treatments for retinal and ocular surface diseases. During his tenure at Genentech, Mr. Campbell was a key leader for the commercial build and launch of Lucentis ® , the first anti-VEGF-A treatment approved for wet AMD; he served in commercial leadership roles through the lifecycle of Lucentis ®, including the expansion into Diabetic Macula Edema, and Retinal Vein Occlusion. He also contributed to the pre-launch commercial planning of Beovu ® in wet AMD at Novartis, as well as the $3.4 billion divestiture of Xiidra ® for Dry Eye Disease to Novartis, during his tenure at Shire. Mr. Campbell most recently served as Senior Vice President and Head of Commercial at Viatris Eye Care which acquired Oyster Point Pharma, where he led the commercial build for the launch of Tyrvaya ® in Dry Eye Disease. Mr. Campbell holds a Bachelor of Science degree from Auburn University and is an Executive Education graduate from the University of Pennsylvania, Wharton School of Business.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636 , and ShORe, NCT04757610 ) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn .
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
| Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 | Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com |
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ**
What specific commercial insights do you anticipate sharing regarding the market potential for sozinibercept in the treatment of wet AMD, as presented by Opthea Limited (OPT)?
Can you elaborate on the key components of Opthea Limited (OPT)’s readiness plans to ensure successful market entry for sozinibercept, especially in combination with anti-VEGF-A therapies?
How does Opthea Limited (OPT) plan to address the current medical needs and vision outcomes in wet AMD, and what role will sozinibercept play in transforming treatment paradigms?
What steps is Opthea Limited (OPT) taking to prepare for the anticipated topline data readout for the COAST and ShORe trials, and how might this influence the commercial strategy for sozinibercept?
4. Considering the insights that will be shared during the presentations, how will Opthea Limited CKDXF measure the commercial potential and success of sozinibercept in the treatment landscape for wet AMD?
**MWN-AI FAQ is based on asking OpenAI questions about Opthea Limited (OTC: CKDXF).
NASDAQ: CKDXF
CKDXF Trading
0.0% G/L:
$0.44 Last:
9,900 Volume:
$0.44 Open:
